ABIVAX Société Anonyme (NASDAQ:ABVX) Receives Consensus Rating of “Moderate Buy” from Analysts

ABIVAX Société Anonyme (NASDAQ:ABVX) has been given an average recommendation of “Moderate Buy” by the six analysts that are presently covering the firm, Marketbeat.com reports. One analyst has rated the stock with a hold rating and five have issued a buy rating on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $34.20.

A number of research firms have recently commented on ABVX. Morgan Stanley raised their price target on ABIVAX Société Anonyme from $15.00 to $16.00 and gave the stock an “equal weight” rating in a research report on Thursday, April 11th. Guggenheim assumed coverage on shares of ABIVAX Société Anonyme in a report on Monday, April 29th. They issued a “buy” rating and a $50.00 price target for the company. BTIG Research began coverage on shares of ABIVAX Société Anonyme in a report on Monday, May 20th. They set a “buy” rating and a $43.00 price objective on the stock. Finally, Piper Sandler started coverage on ABIVAX Société Anonyme in a report on Monday, April 29th. They set an “overweight” rating and a $42.00 target price for the company.

ABIVAX Société Anonyme Trading Up 0.8 %

ABVX opened at $13.10 on Tuesday. The company has a fifty day simple moving average of $13.81 and a 200 day simple moving average of $13.44. The company has a debt-to-equity ratio of 0.23, a quick ratio of 4.08 and a current ratio of 4.08. ABIVAX Société Anonyme has a 12 month low of $7.99 and a 12 month high of $17.02.

Institutional Inflows and Outflows

A number of hedge funds have recently bought and sold shares of the stock. Franklin Resources Inc. bought a new stake in ABIVAX Société Anonyme in the fourth quarter valued at approximately $13,630,000. Capstone Investment Advisors LLC acquired a new stake in ABIVAX Société Anonyme during the 4th quarter valued at $618,000. Ghisallo Capital Management LLC bought a new position in ABIVAX Société Anonyme during the fourth quarter worth $642,000. Commodore Capital LP acquired a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at $20,277,000. Finally, Blackstone Inc. bought a new position in shares of ABIVAX Société Anonyme in the fourth quarter valued at about $25,345,000. 47.91% of the stock is currently owned by institutional investors.

ABIVAX Société Anonyme Company Profile

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stablize the immune response in patients with chronic inflammatory diseases. The company is evaluating its lead drug candidate, obefazimod, in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis in adults.